Tackling cisplatin resistance in ovarian cancer: what can we do?

Ovarian cancer is a complex disease mainly consisting of epithelial cancer which comprises various histological subtypes.The most frequent one is high-grade serous ovarian carcinoma.The prognosis of this disease is poor because most women are diagnosed with advanced disease.Although many patients respond to first-line Pt-based therapy,the development of resistance limits the efficacy of therapy.Novel therapeutic strategies to improve the efficacy of ovarian carcinoma treatment are emerging from both basic and translational research efforts.In this Special Issue,approaches to improve the armamentarium to fight ovarian carcinoma are presented,thereby providing an overview of selected aspects of ovarian cancer biology that can be exploited to improve treatment.In this context,a re-evaluation and optimization of already tested strategies such as intra-peritoneal therapy together with a deep investigation of the recently acquired knowledge on factors(e.g.,E3 ubiquitin ligases)and features[Cancer Stem Cells(CSCs)]contributing to drug resistance may provide useful insights to tackle cisplatin resistance.